JOHN RICE: Open Payments
NPI 1538546874 · RUSSELLVILLE, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$982 in 47 payments from 15 companies in 2025. Trend: 2023 $1,317 · 2024 $363 · 2025 $982
Food & beverage: $871Education: $111
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $262 |
| UCB, Inc. | 4 | $154 |
| Teva Pharmaceuticals USA, Inc. | 4 | $143 |
| Amgen Inc. | 4 | $77 |
| Novartis Pharmaceuticals Corporation | 4 | $72 |
| Genentech USA, Inc. | 3 | $49 |
| SK Life Science, Inc. | 2 | $42 |
| SANOFI PASTEUR INC. | 1 | $33 |
| Neurocrine BioSciences, Inc. | 1 | $32 |
| Organon LLC | 1 | $28 |
Products named: Bimzelx, RINVOQ, SKYRIZI, KESIMPTA, ENBREL, Actemra, QULIPTA, BEYFORTUS.
Industry payments across AR — which companies pay providers there.
